Wang W, Hahn K H, Bishop J F, Gao D Q, Jose P A, Mouradian M M
Genetic Pharmacology Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892-1406, USA.
Synapse. 1996 Jul;23(3):232-5. doi: 10.1002/(SICI)1098-2396(199607)23:3<232::AID-SYN13>3.0.CO;2-0.
The effects of 14 days neuroleptic treatment on the expression of the D3 dopamine receptor gene was investigated in rats using a sensitive polymerase chain reaction assay. In olfactory tubercle, D3 mRNA levels increased following haloperidol (40%), pimozide (56%), and sulpiride (63%) administration, and in nucleus accumbens, levels increased after haloperidol (50%) and sulpiride (50%). D3 expression in the motor striatum did not change with any antagonist tested. Clozapine did not affect D3 expression in any brain region. These data suggest that dopamine antagonists can regulate the expression of the D3 receptor in a brain region selective manner. The findings also suggest that the motor complications of chronic antipsychotic therapy are not due to D3 receptor up-regulation in the striatum.
利用灵敏的聚合酶链反应分析法,研究了14天的抗精神病药物治疗对大鼠D3多巴胺受体基因表达的影响。在嗅结节中,给予氟哌啶醇(增加40%)、匹莫齐特(增加56%)和舒必利(增加63%)后,D3 mRNA水平升高;在伏隔核中,给予氟哌啶醇(增加50%)和舒必利(增加50%)后,水平升高。在运动纹状体中,D3的表达不受任何测试拮抗剂的影响。氯氮平对任何脑区的D3表达均无影响。这些数据表明,多巴胺拮抗剂可以以脑区选择性的方式调节D3受体的表达。研究结果还表明,慢性抗精神病治疗的运动并发症并非由于纹状体中D3受体上调所致。